Dermira Inc. (NASDAQ:DERM) CFO Andrew Guggenhime sold 10,900 shares of Dermira stock in a transaction on Tuesday, October 11th. The shares were sold at an average price of $34.34, for a total value of $374,306.00. Following the sale, the chief financial officer now directly owns 16,016 shares of the company’s stock, valued at $549,989.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Andrew Guggenhime also recently made the following trade(s):
- On Monday, September 19th, Andrew Guggenhime sold 15,000 shares of Dermira stock. The shares were sold at an average price of $35.01, for a total value of $525,150.00.
- On Monday, September 12th, Andrew Guggenhime sold 10,000 shares of Dermira stock. The shares were sold at an average price of $32.53, for a total value of $325,300.00.
- On Thursday, August 11th, Andrew Guggenhime sold 10,000 shares of Dermira stock. The shares were sold at an average price of $31.02, for a total value of $310,200.00.
Dermira Inc. (NASDAQ:DERM) opened at 32.99 on Wednesday. Dermira Inc. has a 52-week low of $17.42 and a 52-week high of $36.16. The company’s market capitalization is $1.17 billion. The stock has a 50 day moving average price of $33.56 and a 200 day moving average price of $30.32.
Dermira (NASDAQ:DERM) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.86) by $0.03. On average, equities analysts expect that Dermira Inc. will post ($3.46) earnings per share for the current year.
DERM has been the subject of a number of research analyst reports. Zacks Investment Research raised Dermira from a “sell” rating to a “hold” rating in a research report on Friday, July 8th. Leerink Swann reaffirmed a “buy” rating on shares of Dermira in a research report on Wednesday, October 5th. Finally, Needham & Company LLC reaffirmed a “positive” rating and set a $46.00 target price on shares of Dermira in a research report on Monday, October 3rd. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $41.00.
Several large investors have recently bought and sold shares of DERM. JPMorgan Chase & Co. raised its position in shares of Dermira by 6,034.5% in the second quarter. JPMorgan Chase & Co. now owns 3,558 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 3,500 shares during the last quarter. Glenmede Trust Co. NA acquired a new position in shares of Dermira during the second quarter valued at $170,000. A.R.T. Advisors LLC acquired a new position in shares of Dermira during the second quarter valued at $207,000. DIAM Co. Ltd. acquired a new position in shares of Dermira during the second quarter valued at $231,000. Finally, Prudential Financial Inc. acquired a new position in shares of Dermira during the second quarter valued at $253,000. 82.57% of the stock is owned by hedge funds and other institutional investors.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.